Tegafur, Gimeracil, Oteracil

5 trials 2 recruiting LOncology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

5 Sponsors

11 Countries

Phase III

Phase II

Phase III/IV

Phase III: 2 Phase II: 2 Phase III/IV: 1

Indications tested

Rectal cancer recurrent 1 Triple negative breast cancer 1

Sponsors using this IMP

Amsterdam UMC 1 Catharina Ziekenhuis Stichting 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 HUS-Yhtymae 1 Region Midtjylland 1

All trials

5 total

Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Phase III 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
OPTIMISE Recruiting

2023-509814-12-00 Phase II 3 countries Region Midtjylland
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus… Recruiting

2024-512526-28-00 Phase III 5 countries Catharina Ziekenhuis Stichting
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati… Ended

2023-509463-24-01 Phase II 4 countries Amsterdam UMC
DPDIMP#1-trial: Impact of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy Ended

2024-518448-20-00 Phase III/IV 1 country HUS-Yhtymae

Showing 1–5 of 5 trials

← All drugs A–Z